Evidence map›Paper›PMID 29023230›Full record

ArticlePreventing chronic disease2017

A Diabetic Retinopathy Screening Tool for Low-Income Adults in Mexico.

Kenny Mendoza-Herrera, Amado D Quezada, Andrea Pedroza-Tobías, Cesar Hernández-Alcaraz, Jans Fromow-Guerra, Simón Barquera

Open access · diamondAbstract readValidation Study
In one paragraph

Article in Preventing chronic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Nomogram for Prediction of Diabetic Retinopathy Among Type 2 Diabetes Population in Xinjiang, China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kenny Mendoza-HerreraCenter for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Morelos, México.
Amado D QuezadaCenter for Evaluation and Surveys Research, National Institute of Public Health, Cuernavaca, Morelos, México.
Andrea Pedroza-TobíasCenter for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Morelos, México.
Cesar Hernández-AlcarazCenter for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Morelos, México.
Jans Fromow-GuerraAssociation for the Prevention of Blindness in Mexico, México City, México.
Simón BarqueraCenter for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Morelos, México.
National Institute of Public Health · SI

Funding

Enhancing Mexican Capacity for CVD Policy ResearchR03TW009061 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIBBINS-DOMINGO, KIRSTEN, FERNANDEZ, ALICIA · 2013 to 2015
$156k
FIC NIH HHS R03 TW009061
6 · The paper itself

Abstract

introductionA national diabetic retinopathy screening program does not exist in Mexico as of 2017. Our objective was to develop a screening tool based on a predictive model for early detection of diabetic retinopathy in a low-income population.

methodsWe analyzed biochemical, clinical, anthropometric, and sociodemographic information from 1,000 adults with diabetes in low-income communities in Mexico (from 11,468 adults recruited in 2014-2016). A comprehensive ophthalmologic evaluation was performed. We developed the screening tool through the following stages: 1) development of a theoretical predictive model, 2) performance assessment and validation of the model using cross-validation and the area under the receiver operating characteristic curve (AUC ROC), and 3) optimization of cut points for the classification of diabetic retinopathy. We identified points along the AUC ROC that minimized the misclassification cost function and considered various scenarios of misclassification costs and diabetic retinopathy prevalence.

resultsTime since diabetes diagnosis, high blood glucose levels, systolic hypertension, and physical inactivity were considered risk factors in our screening tool. The mean AUC ROC of our model was 0.780 (validation data set). The optimized cut point that best represented our study population (z = -0.640) had a sensitivity of 82.9% and a specificity of 61.9%.

conclusionWe developed a low-cost and easy-to-apply screening tool to detect people at high risk of diabetic retinopathy in Mexico. Although classification performance of our tool was acceptable (AUC ROC > 0.75), error rates (precision) depend on false-negative and false-positive rates. Therefore, confirmatory assessment of all cases is mandatory.

Indexed as

AgedCost-Benefit AnalysisDiabetes Mellitus, Type 2Diabetic RetinopathyFemaleHumansMaleMass ScreeningMexicoMiddle AgedPovertyPredictive Value of TestsRisk FactorsROC CurveTime Factors

Identifiers

PMID29023230
PMCPMC5645201
OpenAlexW2762008928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.